Protein Engineering of DAB-IL-2 Fusion Toxins to Increase Biologic Potency-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Protein Engineering of DAB-IL-2 Fusion Toxins to Increase Biologic Potency

Published:1991-12 Issue:1 Antigen and C Volume:636 Page:331-339
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann NY Acad Sci

Author:

KIYOKAWA TETSUYUKI,WILLIAMS DIANE P.,SNIDER CATHERINE E.,WATERS CORY A.,NICHOLS JEAN C.,STROM TERRY B.,MURPHY JOHN R.

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1749-6632.1991.tb33463.x/fullpdf

Reference43 articles.

1. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein.

2. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein

3. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.

4. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

5. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An electrochemiluminescence assay for quantification of Denileukin Diftitox and its anti-drug antibodies in rat serum;Journal of Pharmacological and Toxicological Methods;2023-01

2. Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak®on CD25+cells;OncoImmunology;2014-03

3. Novel Systemic Drugs for Cutaneous T-Cell Lymphoma;Recent Patents on Anti-Cancer Drug Discovery;2011-01-01

4. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma;British Journal of Haematology;2007-08

5. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497;Leukemia & Lymphoma;2007-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3